Browse by Medical Category
Accepting New Patients
Matthew Smith, M.D., Ph.D. is the Director of the Genitourinary Malignancies Program at the Massachusetts General Hospital Cancer Center. His clinical practice and research program focus on the management of prostate cancer.
Go To Programs
Go To Programs
Go To Specialties
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
View my most recent publications at PubMed
A clinical trial led by investigators at Massachusetts General Hospital and University of California, San Francisco found that treatment with an investigational androgen receptor inhibitor significantly delayed the development of metastasis in patients with prostate cancer that had become resistant to standard androgen-deprivation therapy.
An international clinical trial has found that treatment with a drug that suppresses the normal breakdown of bone can delay the development of bone metastases in men with prostate cancer.
Matthew Smith, MD, PhD, of the Massachusetts General Hospital Cancer Center, led a study on a new targeted therapy to stop bone loss, increase bone density and prevent spinal fractures in men receiving androgen-deprivation therapy for prostate cancer.
Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer.
Back to Top